Shenzhen S.E.
06:00:00 2024-06-13 pm EDT
5-day change
1st Jan Change
5.44
CNY
-0.37%
-2.16%
-7.48%
Changzhou Qianhong Biopharma Co.,Ltd Announces Executive Changes
September 25, 2017 at 11:32 am EDT
At the Extraordinary General Meeting held on 22 September 2017, Changzhou Qianhong Biopharma Co.,Ltd approved the election of Wang Yaofang, Zhao Gang, Wang Ke, Jiang Wenqun and Liu Jun as non-independent directors and Rong Xinghua, Shao Rong and Zhang Jiwen as independent directors of the company. Elected Jiang Jianping and Zhang Zhuqing as non-employee supervisors.
Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024
May. 21
CI
Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023
Apr. 26
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 25
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 25
CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on January 3, 2024.
Mar. 22
CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on January 3, 2024 has closed with 25,000,000 shares, representing 1.95% for CNY 140.76 million.
Mar. 21
CI
Changzhou Qianhong Biopharma CO.,LTD Approves Board Elections
Jan. 22
CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 170 million worth of its shares.
Jan. 03
CI
Changzhou Qianhong Biopharma CO.,LTD authorizes a Buyback Plan.
Jan. 01
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-24
CI
Changzhou Qianhong Biopharma CO.,LTD(XSEC:002550) added to S&P Global BMI Index
23-09-18
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-21
CI
Changzhou Qianhong Biopharma Co.,Ltd Announces Cash Dividend on A Shares for 2022, Payable on May 26, 2023
23-05-18
CI
Changzhou Qianhong Biopharma CO.,LTD Approves Cash Dividend for 2022
23-05-12
CI
Tranche Update on Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback Plan announced on April 15, 2023.
23-04-19
CI
Changzhou Qianhong Biopharma CO.,LTD's Equity Buyback announced on April 15, 2023 has closed with 5,000,000 shares, representing 0.39% for CNY 30.09 million.
23-04-18
CI
Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for 2022
23-04-17
CI
Changzhou Qianhong Biopharma CO.,LTD announces an Equity Buyback for CNY 34 million worth of its shares.
23-04-14
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-14
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-14
CI
Changzhou Qianhong Biopharma Co.,Ltd authorizes a Buyback Plan.
23-04-12
CI
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-26
CI
Qianhong Bio Pharma to Invest $85 Million in New Drug Production Base
22-09-22
MT
Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-08
CI
Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2021, Payable on 25 May 2022
22-05-18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
More about the company
Last Close Price
5.44
CNY
Average target price
6.48
CNY
Spread / Average Target
+19.12%
Consensus
1st Jan change
Capi.
-7.48% 937M +41.96% 630B -7.15% 350B +18.77% 328B +8.79% 298B +18.02% 246B +1.27% 225B +11.95% 218B +3.68% 160B -4.38% 156B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD 
